Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens

被引:46
作者
Pushko, Peter [1 ]
Tretyakova, Irina [1 ]
Hidajat, Rachmat [1 ]
Zsak, Aniko [2 ]
Chrzastek, Klaudia [2 ]
Tumpey, Terrence M. [3 ]
Kapczynski, Darrell R. [2 ]
机构
[1] Medigen Inc, 8420 Gas House Pike,Suite S, Frederick, MD 21701 USA
[2] USDA SEPRL, 934 Coll Stn Rd, Athens, GA USA
[3] CDC, Influenza Div, 1600 Clifton Rd NE, Atlanta, GA USA
关键词
Influenza; Avian flu; Vaccine; Recombinant; Virus-like particle; VLP; INTRANASAL VACCINATION; RESPONSES; FERRETS; VACCINES; POULTRY; STRAINS; H10N8; BIRDS; MICE;
D O I
10.1016/j.virol.2016.12.001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Avian influenza (AI) viruses circulating in wild birds pose a serious threat to public health. Human and veterinary vaccines against AI subtypes are needed. Here we prepared triple-subtype VLPs that co-localized H5, H7 and H9 antigens derived from H5N1, H7N3 and H9N2 viruses. VLPs also contained influenza N1 neuraminidase and retroviral gag protein. The H5/H7/H9/N1/gag VLPs were prepared using baculovirus expression. Biochemical, functional and antigenic characteristics were determined including hemagglutination and neuraminidase enzyme activities. VLPs were further evaluated in a chicken AI challenge model for safety, immunogenicity and protective efficacy against heterologous AI viruses including H5N2, H7N3 and H9N2 subtypes. All vaccinated birds survived challenges with H5N2 and H7N3 highly pathogenic AI (HPAI) viruses, while all controls died. Immune response was also detectable after challenge with low pathogenicity AI (LPAI) H9N2 virus suggesting that H5/H7/H9/N1/gag VLPs represent a promising approach for the development of broadly protective AI vaccine.
引用
收藏
页码:176 / 182
页数:7
相关论文
共 36 条
[1]  
Awad E. T., 2015, The Journal of American Science, V11, P1
[2]   Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin [J].
Bright, Rick A. ;
Carter, Donald M. ;
Daniluk, Shannon ;
Toapanta, Franklin R. ;
Ahmad, Attiya ;
Gavrilov, Victor ;
Massare, Mike ;
Pushko, Peter ;
Mytle, Nutan ;
Rowe, Thomas ;
Smith, Gale ;
Ross, Ted M. .
VACCINE, 2007, 25 (19) :3871-3878
[3]  
CDC, 2016, AV INFL CURR SIT
[4]   Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles [J].
Chen, Benjamin J. ;
Leser, George P. ;
Morita, Eiji ;
Lamb, Robert A. .
JOURNAL OF VIROLOGY, 2007, 81 (13) :7111-7123
[5]  
Cox Manon M J, 2015, Ther Adv Vaccines, V3, P97, DOI 10.1177/2051013615595595
[6]   Influenza Neuraminidase as a Vaccine Antigen [J].
Eichelberger, Maryna C. ;
Wan, Hongquan .
INFLUENZA PATHOGENESIS AND CONTROL - VOL II, 2015, 386 :275-299
[7]  
Fao U., 2016, RATIONAL USE VACCINA
[8]  
Freidl G.S., 2014, EUR SURVEILL, V19
[9]   Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge [J].
Galarza, JM ;
Latham, T ;
Cupo, A .
VIRAL IMMUNOLOGY, 2005, 18 (01) :244-251
[10]   Novel Eurasian Highly Pathogenic Avian Influenza A H5 Viruses in Wild Birds, Washington, USA, 2014 [J].
Ip, Hon S. ;
Torchetti, Mia Kim ;
Crespo, Rocio ;
Kohrs, Paul ;
DeBruyn, Paul ;
Mansfield, Kristin G. ;
Baszler, Timothy ;
Badcoe, Lyndon ;
Bodenstein, Barbara ;
Shearn-Bochsler, Valerie ;
Killian, Mary Lea ;
Pedersen, Janice C. ;
Hines, Nichole ;
Gidlewski, Thomas ;
DeLiberto, Thomas ;
Sleeman, Jonathan M. .
EMERGING INFECTIOUS DISEASES, 2015, 21 (05) :886-890